Search By:
Products
Injury
Topic
Company
Industry
Merck and Schering-Plough may have created further risk of injury to patients taking Vytorin by failing to promptly disclose that patients on Vytorin in clinical studies demonstrated increase in plaque deposits in arteries.
Investigation Source
- Arizona
Investigation Scope
Category Information
Investigation Topics
- Increased Risk of Bodily Injury
- Deceptive Promotion Of Drug
Product or Service
- Vytorin
Injury Types
- Liver Disorders
- Heart Attack
Investigation Details
Investigation and a pending class action lawsuit against the drug companies Merck & Co. Inc. and Schering-Plough Corporation.
The class action complaint was filed on behalf of all Arizona residents who took VYTORIN, a cholesterol reducing drug.
The class action complaint against Merck and Schering Plough includes claims for consumer fraud and requests medical monitoring for class members under Arizona law.
Recently, Merck and Schering-Plough announced that the data from the ENHANCE clinical trials showed that patients who took VYTORIN (a combination of Zetia and Zocor) actually had an increase in the amount of plaque deposited in their arteries when compared to those patients who took Zocor alone. The data reflects that users of VYTORIN may be more at risk to have a heart attack, and have been exposed to an increased risk of liver damage, than those who took Zocor alone. If you or someone you know is concerned about injuries suffered as a result of taking VYTORIN.
Do not change medications without first consulting your doctor.
The class action complaint was filed on behalf of all Arizona residents who took VYTORIN, a cholesterol reducing drug.
The class action complaint against Merck and Schering Plough includes claims for consumer fraud and requests medical monitoring for class members under Arizona law.
Recently, Merck and Schering-Plough announced that the data from the ENHANCE clinical trials showed that patients who took VYTORIN (a combination of Zetia and Zocor) actually had an increase in the amount of plaque deposited in their arteries when compared to those patients who took Zocor alone. The data reflects that users of VYTORIN may be more at risk to have a heart attack, and have been exposed to an increased risk of liver damage, than those who took Zocor alone. If you or someone you know is concerned about injuries suffered as a result of taking VYTORIN.
Do not change medications without first consulting your doctor.
Defendant Details
| Name (Stock Symbol) | Brief Description |
|---|---|
| Merck & Co. Inc. (MRK) | Merck & Co. Inc. is a large pharmaceutical company. |
| Schering-Plough Corporation (SGP) | Schering-Plough Corporation discovers, develops, manufactures, and sells pharmaceuticals worldwide. |